MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10238-025-02031-0

Медицинская библиотека · Clinical and experimental medicine · 2026

Immunotherapy in clear cell renal cell carcinoma: current Status, novel Strategies, and future perspectives.

Chen Xiaoli, Ke Yasi, Huang Xuehong, Chen Jialin, Chen Jianan, Chen Zhiyao

СтатьяОбзорПеревод пока не подготовлен

Аннотация

Clear cell renal cell carcinoma (ccRCC) remains a major clinical challenge, with high rates of recurrence and limited long-term survival despite surgical resection and VEGF-targeted therapy. Immune checkpoint inhibitors (ICIs)-targeting PD-1, PD-L1, and CTLA-4-have revolutionized first-line systemic treatment, particularly in combination with VEGF tyrosine kinase inhibitors or as dual ICI regimens. However, primary and acquired resistance, immune-related adverse events (irAEs), and heterogeneous treatment responses limit the durability of benefit in many patients. This review aims to address a central question: how can immunotherapy for ccRCC evolve from incremental survival extension to durable, potentially curative control? We highlight emerging strategies-including next-generation checkpoint inhibitors (LAG-3, TIM-3, TIGIT), bispecific T cell engagers, cytokine-based agents, CAR-T and TCR-T therapies, and cancer vaccines-designed to enhance and sustain anti-tumor immunity. In parallel, we examine the role of multi-omic and spatial biomarkers, such as PBRM1 mutations, interferon-γ signatures, single-cell spatial atlases, and gut microbiome profiles, in refining patient selection and predicting therapeutic outcomes. This review uniquely integrates mechanistic insights with translational advances, providing a forward-looking synthesis of precision immunotherapy in ccRCC. We also emphasize rational combination strategies, biomarker-guided personalization, and irAE management as key priorities to overcome resistance and improve long-term outcomes.

Для цитирования: Chen Xiaoli, Ke Yasi, Huang Xuehong, Chen Jialin, Chen Jianan, Chen Zhiyao. Immunotherapy in clear cell renal cell carcinoma: current Status, novel Strategies, and future perspectives.. Clinical and experimental medicine. 2026. DOI: 10.1007/s10238-025-02031-0.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.